New device aims to keep oxygen levels up during endoscopy in obese patients

NCT ID NCT06796764

Recruiting now Symptom relief Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new device called the COMBO Endoscopy Oropharyngeal Airway in 580 obese patients undergoing sedated gastrointestinal endoscopy. The device combines oxygen delivery, breathing monitoring, and a bite block to prevent low oxygen levels. Researchers will compare it to a standard nasal cannula to see if it reduces the risk of hypoxia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: COMBO Endoscopy Oropharyngeal Airway (device)
What this could lead to: If it works, this device could reduce dangerous drops in oxygen levels during routine endoscopy in obese patients, making the procedure safer.
What could go wrong: This is a relatively small, early-stage trial testing a device, not a drug. The device may not work better than standard care, and results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm Hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER GASTRIC CANCER HYPOXIA

Contacts and locations

Locations

The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China
The Fourth Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China
Zhejiang Cancer hospital
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.